Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

The Florida State University community mourns the loss of esteemed chemist and noted inventor Robert Holton, whose ...

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in ...

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

Bristol Myers Squibb just agreed to shower BioNTech with cash. BioNTech ( BNTX 20.01%), one of the companies made famous for ...

By Michael Erman (Reuters) -Bristol Myers Squibb will pay $1.5 billion upfront to partner with Germany's BioNTech on an ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...